We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New Cell Lines and Controls for PD-1 Research
Product News

New Cell Lines and Controls for PD-1 Research

New Cell Lines and Controls for PD-1 Research
Product News

New Cell Lines and Controls for PD-1 Research


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "New Cell Lines and Controls for PD-1 Research"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AMSBIO has introduced new cell lines and controls for Programmed Cell Death Protein 1 (PD-1) research, and to test inhibitors of the PD-1 / PD-L1 pathway. The binding of PD-1, a receptor expressed on activated T-cells, to its ligands (PD-L1 and PD-L2) negatively regulates immune responses. PD-1 ligands are highly expressed in many cancers, and their interaction inhibits T-cell activity allowing cancer cells to escape immune surveillance.


The PD-1: PD-Ligands pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes. A PD-1 / NFAT Reporter – Jurkat Cell Line is now available for applications including screening for activators or inhibitors of PD-1 signaling in a cellular context and also for characterizing the biological activity of PD-1 and its interactions with ligands.


AMSBIO has also introduced the accompanying TCR activator / PD-L1 – CHO Recombinant Cell line that is purpose designed for screening for activators or inhibitors of PD-1 signaling as well as screening PD-L1 antibodies for their binding affinity. The functionality of the cell lines was validated using a PD-1:PD-L1 cell-based assay and expression of human PD-1 or PD-L1 in the cell lines was confirmed by Western blotting.


AMSBIO offers a wide range of purified, soluble immunoreceptors involved in key immunosignaling pathways. Additionally, the company offer a number of assay kits that can be used to screen for inhibitors of protein-protein interaction, as well as neutralizing antibodies to serve as positive controls for inhibition.

Advertisement